Xeljanz
Brand for: Tofacitinib
My Prescription
Payment
Select pharmacy
$50.51
Print or send this coupon to your phone
AlbertsonsPowered byAbout Xeljanz
Drug Details
Tofacitinib, marketed as Xeljanz, is an oral medication used to manage various inflammatory conditions. It is effective in treating types of arthritis, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis in children aged 2 and older. Additionally, it is prescribed for moderate-to-severe ulcerative colitis. Tofacitinib works by inhibiting Janus kinase (JAK), a protein that contributes to inflammation, thereby reducing joint pain, swelling, and symptoms of ulcerative colitis such as diarrhea and stomach pain. While it is beneficial for patients who have not responded to other treatments, it is important to be aware of potential side effects such as increased risk of infections, headaches, diarrhea, and more serious issues like heart problems and blood clots. Always consult a healthcare professional before starting this medication to ensure it is appropriate for your condition.
Price history for Xeljanz (brand) & Tofacitinib (generic)
60 Tablets, 5MG
Average retail price for Xeljanz
Average retail price for Tofacitinib
Average SaveHealth price for Tofacitinib
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
Over the last 12 months, the average discount price of Xeljanz is $1757.71 using the SaveHealth savings card. That's an average savings of 70.17% on Xeljanz with our discount card.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Xeljanz (Tofacitinib) dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 5MG | 60 Tablets | $50.71 | $0.85 |
| 10MG | 60 Tablets | $78.00 | $1.30 |
Xeljanz FAQs
Xeljanz works by inhibiting certain enzymes known as Janus kinases (JAKs), which play a role in the inflammatory process. By blocking these enzymes, Xeljanz helps reduce inflammation and modulate the immune response, which can alleviate symptoms in conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Humira and Xeljanz are not the same. They are both medications used to treat certain autoimmune conditions, but they work in different ways and belong to different classes of drugs. Humira is a TNF inhibitor, while Xeljanz is a Janus kinase (JAK) inhibitor. It is important for patients to follow their healthcare provider's recommendations regarding which medication is appropriate for their specific condition.
The safety profiles of Rinvoq (upadacitinib) and Xeljanz (tofacitinib) can vary depending on the individual patient and their specific health conditions. Both medications are Janus kinase (JAK) inhibitors used to treat certain autoimmune conditions, and they carry similar risks, including increased risk of infections, blood clots, and certain cancers. The choice between them should be based on a thorough evaluation by a healthcare provider, considering the patient's medical history, current health status, and specific treatment needs. It is important for patients to discuss the potential risks and benefits of each medication with their healthcare provider to determine the most appropriate option for their situation.
Weight gain is not commonly reported as a side effect of Xeljanz (tofacitinib). However, individuals may experience different side effects, and any unexpected changes in weight should be discussed with a healthcare provider.
It is generally not recommended to take Humira (adalimumab) and Xeljanz (tofacitinib) together. Both medications suppress the immune system and using them concurrently can increase the risk of serious infections and other adverse effects. A healthcare provider should be consulted to determine the most appropriate treatment plan for an individual's specific condition.